11 February 2016 -  The Transparency Commission will consider the reimbursement of sonidegib diphosphate (Odomzo), emtricitabine with elvitegravir and cobicistat and tenofovir alafenamide (Genvoya) and adalimumab (Humira).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-02/ordre_du_jour_ct_17022016_internet.pdf